Dechra Pharmaceuticals PLC
Dechra Pharmaceuticals PLC (DPHAY) Revenue
Annual & quarterly revenue history · segment & region breakdown
DPHAY · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsDechra Pharmaceuticals PLC trailing twelve-month (TTM) revenue is $1.44B, an increase of 11.69% year-over-year from $0.76B in FY2023.
Revenue trend
2023 – 2004 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2023-06-30 | $0.76B | +$0.08B | +11.69% |
| 2022-06-30 | $0.68B | +$0.07B | +12.14% |
| 2021-06-30 | $0.61B | +$0.09B | +18.04% |
| 2020-06-30 | $0.52B | +$0.03B | +6.91% |
| 2019-06-30 | $0.48B | +$0.07B | +18.35% |
| 2018-06-30 | $0.41B | +$0.05B | +13.31% |
| 2017-06-30 | $0.36B | +$0.11B | +45.13% |
| 2016-06-30 | $0.25B | +$0.04B | +21.66% |
| 2015-06-30 | $0.20B | +$0.01B | +5.12% |
| 2014-06-30 | $0.19B | +$0.00B | +2.32% |
Compare revenue vs peers
Drug Manufacturers - GeneralCompare DPHAY revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Dechra Pharmaceuticals PLC receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Dechra Pharmaceuticals PLC reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in GBP.
Data sourced from Dechra Pharmaceuticals PLC's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
DPHAY revenue · 4 questionsDPHAY's trailing twelve-month (TTM) revenue is $1.44B. That is an increase of 11.69% year-over-year from $0.76B in FY2023.
▸ Source: FMP · Dechra Pharmaceuticals PLC SEC filings · GAAP · Dechra Pharmaceuticals PLC SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026